Ascension Sciences is pleased to announce the publication of collaborative research with Food and Beverage Innovation Professor Anubhav Pratap-Singh and his group at the University of British Columbia in the Journal Scientific Reports published by Nature.
Dr. Natalia Sannikova, R&D Manager, and Tomas Skrinskas, Founder & CEO, will speak at an upcoming webinar in February presented by Analytical Cannabis. Register now.
Ascension Sciences is pleased to announce that it has been issued an Import Permit by Health Canada. The permit is effective immediately and will allow ASI to accept shipments of cannabinoids for nanoparticle research.
Ascension Sciences is pleased to announce the completion of a licensed R&D laboratory. With the headquarters based in Vancouver, Canada, the facility will support the research and development pipeline for the Company’s growing Contract Research (CRO) operations.
Ascension Sciences and Complex Biotech Discovery Ventures Announce Partnership to Launch Advanced Analytical Testing Services
This partnership will bring nanoparticle characterization, formulation, spectroscopy, calorimetry, diffraction, and other advanced analytical services to the emerging Canadian and global cannabis industries.
Ascension Sciences is pleased to announce the creation of an Advisory Board and welcome two Scientific Advisors, Dr. Tomaž Einfalt and Dr. Pierrot Harvie. The strategic insights from these industry experts will help ASI execute on both internal and client nanoparticle formulation therapies.
Ascension Sciences is pleased to announce that it has been issued a Research and Development (“R&D”) license under the Cannabis Act and Cannabis Regulations by Health Canada with a five-year term until August 17, 2025.
As part of the Student Work Placements Program, ASI is proud to be recognized as a VFC Employer and a supporter of the Government’s initiative to create over 10,000 paid student work placements in STEM.